Clinical trial
A Phase 2, Prospective, Multinational, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of AMOR-1 as a Treatment of Hypocalcemia Associated With Hypoparathyroidism by Replacement of Currently Used Calcium Supplements (CS) in Adults.
NCT06547151 is registered in ClinicalTrials.gov with Amorphical Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Prospective, Multinational, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of AMOR-1 as a Treatment of Hypocalcemia Associated With Hypoparathyroidism by Replacement of Currently Used Calcium Supplements (CS) in Adults.
- Lead sponsor
- Amorphical Ltd.
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- December 15, 2024
- Completion date
- December 30, 2026
- Enrollment
- 62 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.